Comparative inhibitory potential of differently modified antisense oligodeoxynucleotides on hepatitis C virus translation

European Journal of Clinical Investigation

Volumn 29, Issue 10, 1999, Pages 868-876

  Alt, M ^a   Eisenhardt, S ^b   Serwe, M ^c,d   Renz, R ^a   Engels, J W ^b   Caselmann, W H ^c,d  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d Department of Virus Research ^*  (Germany)

Author keywords

5' non coding region; Antisense oligodeoxynucleotide; Benzylphosphonate modified oligodeoxynucleotide; Hepatitis C virus; Methylphosphonate modified oligodeoxynucleotide; Phosphorothioate ODN

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTIVIRUS AGENT; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REPORTER GENE; RETICULOCYTE LYSATE; RNA CLEAVAGE; VIRUS TRANSCRIPTION;

ANIMALS; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION REGULATION, VIRAL; HEPACIVIRUS; HUMANS; LIVER NEOPLASMS; LUCIFERASES; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PHOSPHONIC ACIDS; PROTEIN BIOSYNTHESIS; RABBITS; RECOMBINANT PROTEINS; RETICULOCYTES; RIBONUCLEASE H, CALF THYMUS; STRUCTURE-ACTIVITY RELATIONSHIP; THIONUCLEOTIDES; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0032882628     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1999.00552.x     Document Type: Article

References (55)

1. 1 Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327 (27): 1899-905.
2. 2 Caselmann WH, Alt M. Hepatitis C virus infection as a major risk factor for hepatocellular carcinoma. J Hepatol 1996; 24 (2 Suppl.): 61-6.
3. 3 Wakita T, Wands JR. Specific inhibition of hepatitis C virus expression by antisense oligodeoxynucleotides. In vitro model for selection of target sequence. J Biol Chem 1994; 269: 14205-10.
4. 4 Alt M, Renz R, Hofschneider PH, Paumgartner G, Caselmann WH. Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides. Hepatology 1995; 22: 707-17.
5. 5 Mizutani T, Kato N, Hirota M, Sugiyama K, Murakami A, Shimotohno K. Inhibition of hepatitis C virus replication by antisense oligonucleotide in culture cells. Biochem Biophys Res Commun 1995; 212: 906-11.
6. 6 Seki M, Honda Y. Phosphorothioate antisense oligodeoxynucleotides capable of inhibiting hepatitis C virus gene expression: in vitro translation assay. J Biochem (Tokyo) 1995; 118: 1199-204.
7. 7 Hanecak R, Brown-Driver V, Fox MC, Azad RF, Furusako S, Nozaki C et al. Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes. J Virol 1996; 70: 5203-12.
8. 8 Vidalin O, Major ME, Rayner B, Imbach JL, Trepo C, Inchauspe G. In vitro inhibition of hepatitis C virus gene expression by chemically modified antisense oligodeoxynucleotides. Antimicrob Agents Chemother 1996; 40: 2337-44.
9. 9 Caselmann WH, Eisenhardt S, Alt M. Synthetic antisense oligodeoxynucleotides as potential drugs against hepatitis C. Intervirol 1997; 40: 394-9.
10. 10 Wu CH, Wu GY. Targeted inhibition of hepatitis C virus-directed gene expression in human hepatoma cell lines. Gastroenterology 1998; 114: 1304-12.
11. 11 Crooke RM, Hoke GD, Shoemaker JE. In vitro toxicological evaluation of ISIS 1082, a phosphorothioate oligonucleotide inhibitor of herpes simplex virus. Antimicrob Agents Chemother 1992; 36: 527-32.
12. 12 Alper J. Oligonucleotides surge into clinical trials. Biotechnology 1993; 11: 1225.
13. 13 Lisziewicz J, Sun D, Weichold FF, Thierry AR, Lusso P, Tang J et al. Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells. Proc Natl Acad Sci USA 1994; 91: 7942-6.
14. 14 Heidenreich O, Kang SH, Xu X, Nerenberg M. Application of antisense technology to therapeutics. Mol Med Today 1995; 1 (3): 128-33.
15. 15 Sharma HW, Narayanan R. The therapeutic potential of antisense oligonucleotides. Bioessays 1995; 17: 1055-63.
16. 16 Narayanan R, Akhtar S. Antisense therapy. Curr Opin Oncol 1996; 8: 509-15.
17. 17 Agrawal S. Antisense oligonucleotides: towards clinical trials. Trends Biotechnol 1996; 14: 376-87.
18. 18 Ho PT, Parkinson DR. Antisense oligonucleotides as therapeutics for malignant diseases. Semin Oncol 1997; 24 (2): 187-202.
19. 19 Crooke ST. Progress in antisense therapeutics. Med Res Rev 1996; 16: 319-44.
20. 20 Gao WY, Hanes RN, Vazquez-Padua MA, Stein CA, Cohen JS, Cheng YC. Inhibition of herpes simplex virus type 2 growth by phosphorothioate oligodeoxynucleotides. Antimicrob Agents Chemother 1990; 34: 808-12.
21. 21 Lisziewicz J, Sun D, Klotman M, Agrawal S, Zamecnik P, Gallo R. Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment. Proc Natl Acad Sci USA 1992; 89: 11209-13.
22. 22 Offensperger WB, Offensperger S, Walter E, Teubner K, Igloi G, Blum HE, Gerok W. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. EMBO J 1993; 12: 1257-62.
23. 23 Stein CA, Krieg AM. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev 1994; 4 (2): 67-9.
24. 24 Agrawal S, Zhao Q. Antisense therapeutics. Curr Opin Chem Biol 1998; 2: 519-28.
25. 25 Crooke RM. In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Anticancer Drug Des 1991; 6: 609-46.
26. 26 Iversen P. In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue. Anticancer Drug Des 1991; 6: 531-8.
27. 27 Gura T. Antisense has growing pains. Sci 1995; 270: 575-7.
28. 28 Agrawal S, Temsamani J, Galbraith W, Tang J. Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet 1995; 28 (1): 7-16.
29. 29 Holt J. Antisense therapeutics. Mol Med Today 1996; 2 (5): 184-5.
30. 30 Benimetskaya L, Tonkinson JL, Koziolkiewicz M, Karwowski B, Guga P, Zeltser R et al. Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P-chirality independent. Nucleic Acids Res 1995; 23: 4239-45.
31. 31 Fennewald SM, Rando RF. Inhibition of high affinity basic fibroblast growth factor binding by oligonucleotides. J Biol Chem 1995; 270: 21718-21.
32. 32 Guvakova MA, Yakubov LA, Vlodavsky I, Tonkinson JL, Stein CA. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem 1995; 270: 2620-7.
33. 33 Krieg AM, Stein CA. Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? (Editorial) Antisense Res Dev 1995; 5 (4): 241.
34. 34 Weidner DA, Valdez BC, Henning D, Greenberg S, Busch H. Phosphorothioate oligonucleotides bind in a non sequence-specific manner to the nucleolar protein C23/nucleolin. FEBS Lett 1995; 366 (2-3): 146-50.
35. 35 Daum T, Engels JW, Mag M, Muth J, Lucking S, Schroder HC et al. Antisense oligodeoxynucleotide: inhibitor of splicing of mRNA of human immunodeficiency virus. Intervirolology 1992; 33 (2): 65-75.
36. 36 Miller PS. Development of antisense and antigene oligonucleotide analogs. Prog Nucleic Acid Res Mol Biol 1996; 52: 261-91.
37. 37 Samstag W, Eisenhardt S, Offensperger WB, Engels JW. Synthesis and properties of new antisense oligodeoxynucleotides containing benzylphosphonate linkages. Antisense Nucl Acid Drug Dev 1996; 6 (3): 153-6.
38. 38 Samstag W, Engels JW. Stereoselective synthesis of phosphate-modified building blocks of DNA. Angew Chem Int Ed Engl 1992; 31: 1386-8.
39. 39 Alt M, Renz R, Hofschneider PH, Caselmann WH. Core specific antisense phosphorothioate oligodeoxynucleotides as potent and specific inhibitors of hepatitis C viral translation. Arch Virol 1997; 142: 589-99.
40. 40 Stein CA, Mori K, Loke SL, Subasinghe C, Shinozuka K, Cohen JS, Neckers LM. Phosphorothioate and normal oligodeoxyribonucleotides with 5′-linked acridine: characterization and preliminary kinetics of cellular uptake. Gene 1988; 72: 333-41.
41. 41 Stein CA, Cheng YC. Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science 1993; 261: 1004-12.
42. 42 Agrawal S. Antisense oligonucleotides as antiviral agents. Trends Biotechnol 1992; 10 (5): 152-8.
43. 43 Shimizu YK, Iwamoto A, Hijikata M, Purcell RH, Yoshikura H. Evidence for in vitro replication of hepatitis C virus genome in a human T-cell line. Proc Natl Acad Sci USA 1992; 89: 5477-81.
44. 44 Shimizu YK, Purcell RH, Yoshikura H. Correlation between the infectivity of hepatitis C virus in vivo and its infectivity in vitro. Proc Natl Acad Sci USA 1993; 90: 6037-41.
45. 45 Müller HM, Pfaff E, Goeser T, Kallinowski B, Solbach C, Theilmann L. Peripheral blood leukocytes serve as a possible extrahepatic site for hepatitis C virus replication. J Gen Virol 1993; 74: 669-76.
46. 46 Woolf TM, Melton DA, Jennings CG. Specificity of antisense oligonucleotides in vivo. Proc Natl Acad Sci USA 1992; 89: 7305-9.
47. 47 Minshull J, Hunt T. The use of single-stranded DNA and RNase H to promote quantitative 'hybrid arrest of translation' of mRNA/DNA hybrids in reticulocyte lysate cell-free translations. Nucleic Acids Res 1986; 14: 6433-51.
48. 48 Cazenave C, Stein CA, Loreau N, Thuong NT, Neckers LM, Subasinghe C et al. Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides. Nucleic Acids Res 1989; 17: 4255-73.
49. 49 Bertrand JR, Rayner B, Imbach JL, Paoletti C, Malvy C. Comparative activity of alpha-and beta-anomeric oligonucleotides on rabbit beta globin synthesis: inhibitory effect of cap targeted alpha-oligonucleotides (published erratum appears in Biochem Biophys Res Commun 1989; 165: 1443). Biochem Biophys Res Commun 1989; 164: 311-8.
50. 50 Crooke ST. Progress in antisense therapeutics. Hematol Pathol 1995; 9 (2): 59-72.
51. 51 Soni PN, Brown D, Saffie R, Savage K, Moore D, Gregoriadis G, Dusheiko GM. Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection. Hepatology 1998; 28: 1402-10.
52. 52 Zhang H, Hanecak R, Brown-Driver V, Azad R, Conklin B, Fox MC, Anderson KP. Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant. Antimicrob Agents Chemother 1999; 43: 347-53.
53. 53 Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase [see comments]. Nature Med 1996; 2 (6): 668-75.
54. 54 Heidenreich O, Gryaznov S, Nerenberg M. RNase H-independent antisense activity of oligonucleotide. N3′→P5′ phosphoramidates. Nucleic Acids Res 1997; 25: 776-80.
55. 55 Stein CA, Tonkinson JL, Zhang LM, Yakubov L, Gervasoni J, Taub R, Rotenberg SA. Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells. Biochem 1993; 32: 4855-61.